EP2768544A1 - Systeme de gelification in situ absorbable, son procede de fabrication et son utilisation - Google Patents

Systeme de gelification in situ absorbable, son procede de fabrication et son utilisation

Info

Publication number
EP2768544A1
EP2768544A1 EP20110874179 EP11874179A EP2768544A1 EP 2768544 A1 EP2768544 A1 EP 2768544A1 EP 20110874179 EP20110874179 EP 20110874179 EP 11874179 A EP11874179 A EP 11874179A EP 2768544 A1 EP2768544 A1 EP 2768544A1
Authority
EP
European Patent Office
Prior art keywords
forming composition
situ gel
group
composition
lactide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20110874179
Other languages
German (de)
English (en)
Other versions
EP2768544A4 (fr
Inventor
Shalaby W. Shalaby
Joel Corbett
Jason OLBRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poly Med Inc
Original Assignee
Poly Med Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poly Med Inc filed Critical Poly Med Inc
Publication of EP2768544A1 publication Critical patent/EP2768544A1/fr
Publication of EP2768544A4 publication Critical patent/EP2768544A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Definitions

  • polyoxyalkylene glycol chain has an average molecular weight of 200-1200 dalton.
  • the polyoxyalkylene glycol chain is PEG 200, PEG 300, PEG 400, PEG 500, PEG 600, PEG 700, PEG 800, PEG 900, PEG 1000, and derivatives thereof.
  • the polyester or polyester-carbonate chain segments are derived from at least one cyclic monomer selected from the group represented by ⁇ -caprolactone, trimethylene carbonate, p-dioxanone, 1 ,5- dioxepan-2-one, 1-lactide, dl-lactide, glycolide, morpholinedione, and combinations thereof.
  • the aliphatic urethane segments are derived from at least one diisocyanate selected from the group consisting of hexamethylene diisocyanate, lysine-derived diisocyanate, and
  • the in situ gel-forming composition forms a hydrogel or semi-solid mass at a treatment site within 15 seconds, 30 seconds, 60 seconds or 90 seconds.
  • the gelation time is determined visually by observing the period between injection and formation of the solid mass.
  • the diluent/solvent portion of the solution precipitates leaving the hardened polymeric hydrogel or semi-solid mass that can be visually detected.
  • the rate of gelation may be adjusted by adding one or more gelation accelerators to the in situ gel-forming composition.
  • Compounds that may serve as gelation accelerators include, but are not limited to, collagen, thrombin, activated platelets, chitosan, fibrinogen and antifibrinolytics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition gélifiante in situ. La composition gélifiante in situ comprend au moins un polymère absorbable, des solvants tels que la N-méthyl-2-pyrrolidone, le polyéthylène glycol ou le DMSO, et facultativement au moins un agent bioactif. La composition forme un hydrogel ou une masse semi-solide lors de sa mise en contact avec un environnement aqueux. L'invention concerne également la méthode d'utilisation de la composition gélifiante in situ dans le cadre de diverses applications.
EP11874179.2A 2011-10-17 2011-10-17 Systeme de gelification in situ absorbable, son procede de fabrication et son utilisation Withdrawn EP2768544A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/056537 WO2013058726A1 (fr) 2011-10-17 2011-10-17 Système de gélification in situ absorbable, son procédé de fabrication et son utilisation

Publications (2)

Publication Number Publication Date
EP2768544A1 true EP2768544A1 (fr) 2014-08-27
EP2768544A4 EP2768544A4 (fr) 2015-06-24

Family

ID=48141188

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11874179.2A Withdrawn EP2768544A4 (fr) 2011-10-17 2011-10-17 Systeme de gelification in situ absorbable, son procede de fabrication et son utilisation

Country Status (5)

Country Link
EP (1) EP2768544A4 (fr)
JP (1) JP5989126B2 (fr)
CN (2) CN107252498B (fr)
CA (1) CA2852386C (fr)
WO (1) WO2013058726A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305892A1 (en) * 2014-04-25 2015-10-29 Abbott Cardiovascular Systems Inc. Methods and Devices for Treating a Bodily Lumen with In Situ Generated Structural Support
CN104189951B (zh) * 2014-09-19 2017-06-30 赣南师范学院 一种注射用快速形成原位小分子水凝胶的液态制剂及其制备方法和应用
CN104383276A (zh) * 2014-10-27 2015-03-04 济南高达信息技术有限公司 一种治疗蜘蛛痣的中药口服液制剂及其制备方法
WO2017024027A1 (fr) * 2015-08-03 2017-02-09 Tolmar International Limited Système de distribution de polymère liquide pour l'administration prolongée de médicaments
JP6835841B2 (ja) * 2015-11-16 2021-02-24 エボニック オペレーションズ ゲーエムベーハー 非核酸系逆転写酵素阻害剤とポリ（ラクチド−ｃｏ−グリコリド）とを含む注射液
WO2017192753A1 (fr) * 2016-05-03 2017-11-09 Bvw Holding Ag Gel multiphasique
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE69636626T2 (de) * 1995-07-28 2007-08-30 Genzyme Corp., Cambridge Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen
EP0923399B1 (fr) * 1996-07-29 2004-06-16 Micro Therapeutics, Inc. Ensemble de pieces pour des nouveaux procedes d'embolisation de sites vasculaires a l'aide d'une composition d'embolisation comprenant du dymethylsulfoxyde
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
AU754003B2 (en) * 1998-06-30 2002-10-31 Amgen, Inc. Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1987847A1 (fr) * 1999-05-21 2008-11-05 Micro Therapeutics, Inc. Nouvelles compositions d'embolisation haute viscosité
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AU2003272011A1 (en) * 2002-10-31 2004-05-25 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
CN1950114A (zh) * 2004-05-12 2007-04-18 苏尔莫迪克斯公司 用于医疗物品的天然生物可降解的多糖涂层
US20050255091A1 (en) * 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
CN1899264A (zh) * 2006-07-20 2007-01-24 上海交通大学 温度敏感型水凝胶释药体系及其制备方法
CN100562358C (zh) * 2007-05-17 2009-11-25 浙江大学 以水凝胶微球为模板制备中空微球的方法
US20090233887A1 (en) * 2008-03-12 2009-09-17 Shalaby Shalaby W Hydroswellable, Segmented, Aliphatic Polyurethanes and Polyurethane Ureas
CN101721349B (zh) * 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 可注射原位交联水凝胶及其制备方法和用途
CN102146200B (zh) * 2011-04-19 2012-08-22 复旦大学 一种基于化学交联凝胶颗粒的温敏性水凝胶及其制备方法

Also Published As

Publication number Publication date
CA2852386C (fr) 2019-05-21
CN103998069A (zh) 2014-08-20
CN107252498B (zh) 2021-02-19
JP2014532082A (ja) 2014-12-04
JP5989126B2 (ja) 2016-09-07
CA2852386A1 (fr) 2013-04-25
WO2013058726A1 (fr) 2013-04-25
CN107252498A (zh) 2017-10-17
EP2768544A4 (fr) 2015-06-24

Similar Documents

Publication Publication Date Title
US20190167839A1 (en) Absorbable in situ gel-forming system, method of making and use thereof
CA2852386C (fr) Systeme de gelification in situ absorbable, son procede de fabrication et son utilisation
Gong et al. Thermosensitive PEG–PCL–PEG hydrogel controlled drug delivery system: sol–gel–sol transition and in vitro drug release study
US7250177B2 (en) Multiblock biodegradable hydrogels for drug delivery and tissue treatment
Xu et al. Accelerated cutaneous wound healing using an injectable teicoplanin-loaded PLGA-PEG-PLGA thermogel dressing
NZ561597A (en) Use of eptifibatide for reducing scar tissue formation
CA3067269C (fr) Compositions de pate polymere pour administration de medicament
CN103179959A (zh) 含悬挂亲水基的可生物降解的组合物和相关器械
Guo et al. Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment
AU2009255675A1 (en) Controlled release copolymer formulation with improved release kinetics
AU2013315142A1 (en) Polytetrafluoroethylene co-polymer emulsions
Liang et al. A Janus hydrogel sealant with instant wet adhesion and anti-swelling behavior for gastric perforation repair
EP3901193A1 (fr) Polymère modifié par un acide aminé pour la prévention de l'adhésion et son application
EP2997982A1 (fr) Substance pour la prévention des adhérences et son procédé de fabrication
JP6403297B2 (ja) 癒着防止材の製造方法
JP6176998B2 (ja) 温度応答性生分解性高分子組成物及びその製造方法
CN115403760B (zh) 用于预防沾粘的氨基酸改质的聚合物及其应用
Huynh et al. Injectable temperature-and pH/temperature-sensitive block copolymer hydrogels
Overstreet Temperature-responsive hydrogels with controlled water content and their development toward drug delivery and embolization applications
Ohya Injectable Hydrogels
Hydrogels CONG TRUC HUYNH AND DOO SUNG LEE
Mawad Development of Novel hydrogels for protein drug delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150527

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 31/00 20060101ALI20150520BHEP

Ipc: A61L 24/00 20060101ALI20150520BHEP

Ipc: A61L 27/14 20060101AFI20150520BHEP

Ipc: A61L 27/58 20060101ALI20150520BHEP

Ipc: A61L 27/54 20060101ALI20150520BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210413